WORLD CONGRESS OF DERMATOLOGY, MILAN, 2019

ipharmaservices
Jun 12, 2019
1 min read

Updated: Jun 12, 2019

ABBVIE

Skyrizi

AbbVie has presented two-year data of Skyrizi (risankizumab) showing complete clearance in patients suffering from plaque psoriasis. Skyrizi is indicated for the treatment of plaque psoriasis in adults and has recently received the approval from European Medicines Agency.

About IMMhance study (Phase 3):

The drug was administered in two phases.

Results: 73% achieved skin clearance, 100% improvement in Psoriasis Area Severity Index was achieved in 72% patients compared to 2% of patients who withdrew the treatment.

Recent Posts

See All

China: NMPA Approves New Therapies | 2026

Rexobin Approved for Pustular Psoriasis Flares July 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treat

Italy | AIFA | Healthcare Updates | iPharmaCenter

AIFA Forms Expert Panels to Support Oncology and Hematology Decisio The Italian Medicines Agency has created two specialist advisory groups focused on cancer care and blood-related malignancies. The i

ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026

Ocrelizumab Secures Expanded Approval for Pediatric Multiple Sclerosis Roche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-r

WORLD CONGRESS OF DERMATOLOGY, MILAN, 2019

ABBVIE

Skyrizi

Recent Posts

Comments

Join our mailing list